Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants

Transplantation

Volumn 72, Issue 6, 2001, Pages 1056-1061

  Staatz, Christine E ^a   Taylor, Paul J ^a,b   Lynch, Stephen V ^a   Willis, Charlene ^a   Charles, Bruce G ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; TACROLIMUS;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; NEWBORN; PREDICTION; PRIORITY JOURNAL;

EID: 0035959914     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200109270-00013     Document Type: Article

References (55)

1. Long-term outcomes in paediatric liver recipients: Comparison between cyclosporin A and tacrolimus
2. The use of tacrolimus in paediatric liver transplantation
3. Clinical pharmacokinetics of tacrolimus
4. Japanese study of FK506 on kidney transplantation: The benefit of monitoring the whole blood FK506 concentrations in patients
5. Pharmacokinetics of tacrolimus in liver transplant patients
6. Pharmacokinetics of FK506 in transplant patients
7. Pharmacokinetics and monitoring of FK506 [Tacrolimus]
8. Population pharmacokinetics of tacrolimus in liver transplant patients
9. Pharmacokinetics of FK506 during maintenance therapy in liver transplant patients
10. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion
11. Comparative study of cyclosporine and FK506 dosage requirements in adult and paediatric liver transplant patients
12. Effects of hepatic dysfunction and T-tube clamping on FK506 pharmacokinetics and trough concentrations
13. Pharmacokinetics of tacrolimus (FK506) in liver transplant patients
14. Population pharmacokinetics of tacrolimus (FK506) in liver transplant patients
15. Pharmacokinetics of FK506: Preclinical and clinical studies
16. Pharmacokinetics of FK506 following oral administration: A comparison of FK506 and cyclosporine
17. Uptake of FK506 by lymphocytes and erythrocytes
18. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes
19. Plasma protein binding of tacrolimus in humans
20. Cytochrome P4503A enzymes are responsible for biotransformation of FK506 and rapamycin in man and dog
21. In vitro metabolism of FK506 in rat, rabbit and human liver microsomes: Identification of a major metabolite and of cytochrome P4503A as the major enzymes responsible for its metabolism
22. Cyclosporin pharmacokinetics in paediatric transplant recipients
23. Suggested guidelines for the use of tacrolimus in paediatric liver transplant patients
24. Therapeutic monitoring of tacrolimus in paediatric and adult transplant patients
25. Differences in oral FK506 dose requirements between adult and paediatric liver transplant patients
26. Monitoring of tacrolimus as rescue therapy in paediatric liver transplantation
27. Experience with FK506 in living-related liver transplantation
28. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates
29. Population pharmacokinetics and pharmacodynamics: An underutilised resource
30. Pharmacostatistical modelling for observational data
31. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data
32. Population pharmacokinetics/dynamics
33. Bayesian parameter estimation and population pharmacokinetics
34. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry
35. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes
36. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes
37. Interactions of FK506 (tacrolimus) with clinically important drugs
38. Clinically significant drug interactions with new immunosuppressive agents
39. Tacrolimus dose is donor age dependent
40. Cytochrome P450 3A ontogeny and drug disposition
41. Human cytochrome P450 maximal activities in paediatric versus adult liver
42. Liver volume as a determinate of drug clearance in children and adolescents
43. Liver volume in children measured by computed tomography
44. Evidence that host size determines liver size: Studies in dogs receiving orthotopic liver transplants
45. Oral tacrolimus (FK506) induction therapy in paediatric orthotropic liver transplantation
46. The effect of graft function on FK506 plasma levels, dosage and renal function, with particular reference to the liver
47. Influence of post-transplant time on dose and concentration of tacrolimus in liver transplant patients
48. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation
49. Pharmacokinetics and pharmacodynamics of FK506 in paediatric patients receiving living-related donor liver transplantations
50. Pharmacokinetics of FK506 in living-related liver transplantation
51. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients
52. FK506 trough levels in whole blood and plasma in liver transplant recipients